Clinical Observation of Recombinant Bovine Basic Fibroblast Growth Factor Eye Gel Combined with Tobramycin Dexamethasone Eye Drops in the Treatment of Dry Eye Syndrome in Patients after Cataract Surgery

Objective:To evaluate the therapeutic effect of recombinant bovine basic fibroblast growth factor(rbFGF)eye gel combined with tobramycin-dexamethasone(TOB-Dex)eye drops on dry eye syndrome(DES)after cataract surgery.Methods:86 patients with DES after cataract surgery,admitted from November 2021 to November 2023,were randomly divided into groups.The observation group included 43 patients treated with rbFGF eye gel combined with TOB-Dex eye drops.The reference group included 43 patients treated with TOB-Dex eye drops alone.Multiple indicators,including total effective rate and clinical symptom scores,were compared between the two groups.Results:The total effective rate in the observation group was higher than in the reference group(P<0.05).Before treatment,there were no differences in clinical symptom scores,serum factors,or disease severity scores between the two groups(P>0.05).Three weeks after treatment,the observation group had lower clinical symptom scores,serum factors,and disease severity scores compared to the reference group(P<0.05).The adverse reaction rate in the observation group was lower than in the reference group(P<0.05).Conclusion:rbFGF eye gel combined with TOB-Dex eye drops can improve the clinical efficacy for patients with DES after cataract surgery,alleviate disease symptoms,reduce inflammatory responses,and have fewer adverse reactions.

Effect of basic fibroblast growth factor(bFGF) on the treatment of exposure of the orbital implants

Objective: To evaluate the efficacy and the indication of basic fibroblast growth factor (bFGF) in the treatment of exposure of orbital implants. Design: Retrospective and observational case series. Methods: We reviewed 41 patients (41 eyes) suffering exposure of orbital implants from Jan. 2000 to June 2006. The study group patients with mild exposure received com-bined treatment with bFGF and antibiotic drops, and while the control group patients with mild exposure were treated with anti-biotic drops only. The study group patients with moderate and severe exposure received combined treatment with bFGF and antibiotic drops, and after 2 months they were subjected to amniotic membrane transplantation, while the control group patients with moderate and severe exposure underwent amniotic membrane transplantation after using antibiotic drops. Observation of the growth of conjunctival epithelium and comparison of the healing rate of the two groups. Results: The healing rates of the mild, moderate and severe exposure study group were 100% and 92.3%. The healing rates of the mild, moderate and severe exposure control group were 55.6% and 66.7% respectively. The difference of the healing rates of the mild exposure study group and the control group was significant (P=0.033). And the difference of the healing rates of the moderate and severe exposure study group and the control group was not significant (P=0.167). Conclusion: bFGF may promote obviously the healing of orbital implant exposure, particularly it can be the first choice for the treatment of mild degree exposure. For the moderate and severe cases, it can be administered before surgical repair to enhance neovascularization and will tend to increase the success rate of surgical repair.

Successful Management of Wound Dehiscence after Total Knee Arthroplasty by Topically Using Recombinant Basic Fibroblast Growth Factor

Wound complications are estimated to be affected in about 9% of TKA patients, which may increase the risk of deep periprosthetic infection and results in re-operation, joint fusion, or amputation. Here we have reported a female patient who suffered wound rupture due to early post-operation mobilization and weight-bearing. The wound dehiscence was successfully managed by applying recombinant basic fibroblast growth factor-2 and anti-infective treatment without removing prosthetic joint.

Usefulness of Basic Fibroblast Growth Factor (bFGF) Loaded Dissolving Microneedles for Local Therapy of Skin Wounds

Purpose: The usefulness of dissolving microneedles (DMs) for local skin therapy by basic fibroblast growth factor (bFGF) was studied in rats. Methods: We prepared four kinds of bFGF-loaded DMs, approximately 500 μm length and 300 μm diameter at the bottom. Long-term stability and dissolution studies were performed by HPLC method. Pharmacokinetic and pharmacological evaluations were performed after administration of bFGF loaded DMs to rats. Results: The bFGF contents were 2.15 ± 0.07, 1.07 ± 0.04, 0.56 ± 0.07 and 0.12 ± 0.03 μg. The 100.2 ± 3.4%, 100.2 ± 3.3%, 99.3 ± 1.4% and 100.4 ± 3.0% of bFGF were recovered after 1, 3 and 6 months and 1 year incubation at 40°C. The bFGF was released from DMs within 5 min. In a pharmacokinetic study using 2.0 and 1.0 μg bFGF-loaded DMs, no systemic exposure of bFGF was detected. The initial bFGF concentrations in the rat skin tissue after administration of bFGF-loaded DMs to the hair-removed rat abdominal skin were 510.2 ± 20.1 ng/g wet weight for 2 μg bFGF DMs and 264.2 ± 56.5 ng/g wet weight for 1 μg DMs, declining slowly thereafter to 226.3 ± 33.5 and 105.1 ± 27.4 ng/g wet weight at 6 hr after administration. Good dose-dependency was observed. Pharmacological evaluation of bFGF-loaded DMs of 2.0, 1.0, 0.5, and 0.1 μg, in the wound healing rat model, all used DMs, but 0.1 μg DMs, showed good healing effects. Considered collectively, these results suggest the usefulness of bFGF-loaded DMs for local therapy of skin wound disease.

THE EFFECT OF BASIC FIBROBLAST GROWTH FACTOR SLOW-RELEASE MICROCAPSULES ON ANGIOGENESIS IN INFARCTED RABBIT MYOCARDIUM

Objectives To observe the effect of basic fibroblast growth factor (bFGF) slow-release microcapsules on angiogenesis in infarcted myocardial regions. Methods.Myocardial infarction was induced in 24 New Zealand rabbits by ligating the root of left anterior descending coronary artery.Group Ⅰ(n=8) served as control, group Ⅱ(n=8) as a blank microcapsule group, group Ⅲ(n=8, each microcapsule contains 1μg bFGF) as micrpcapsule group.In group Ⅱ and Ⅲ, 5 blank microcapsules or bFGF slow-release microcapsules were implanted into myocardium underneath the epicardium between the left anterior descending coronary artery and left circumflex artery.Infarct size was evaluated by infarcted weight/left ventricle weight ratio and angiogenesis was evaluated by immunohistochemical examinations 5 weeks later. [WT5”BX] Results.As compared with group Ⅰ and Ⅱ, rabbits treated with bFGF slow-release microcapsules showed higher microvessel counts (group Ⅰ3775±450, group Ⅱ3837±498,vs.group Ⅲ 13550±481,P<0001) and less infarcted weight /left ventricle weight (group Ⅰ168%±04%,group Ⅱ167%±05%,vs.group Ⅲ 70%±02%,P<0001). Conclusions.Subepicardial administration of bFGF slow-release microcapsule in the infarcted rabbit model results in effective angiogenesis and reduction in infarct size.

EXPRESSION AND SIGNIFICANCE OF BASIC FIBROBLAST GWOWTH FACTOR AND FIBROBLAST GROWTH FACTOR RECEPTOR-1 IN OVARIAN EPITHELIAL NEOPLASM

Objective To study the relevance of expression of basic fibroblast growth factor (bFGF), fibroblast growth factor receptor 1 (FGFR 1) and carcinogenesis and progression of ovarian epithelial neoplasm. Methods Ten cases of normal ovarian tissues and 75 cases of ovarian epithelial neoplasm tissues were detected by immunohistochemical methods: S P for bFGF, FGFR 1,double immunohistochemistry Lab SA for Ki 67 antigen and bFGF. Results The expression level of bFGF, FGFR 1in ovarian epithelium and ovarian epithelial neoplasm showed a step wise increase in the following order:normal <benign <borderline <malignant; The expression level and intensity of bFGF and FGFR 1 were increased with the decrease of differentiation degree and increase of clinical stage in ovarian carcinoma; There was no statistical difference between the expression of bFGF, FGFR 1 in serous cystadenocarcinoma and that of mucinous cystadenocarcinoma; The expression of bFGF was correlated with that of FGFR 1 in neoplastic tissues; There were positive expression rates of bFGF and Ki 67 antigen in ovarian epithelial neoplasm. Conclusion As an important proliferative factor, bFGF plays an important role in carcinogenisis and progression of ovarian epithelial neoplasm.

EXPRESSION OF VASCULAR ENDOTHELIAL GROWTH FACTOR AND BASIC FIBROBLAST GROWTH FACTOR IN HUMAN NON-SMALL CELL LUNG CANCER AND THEIR CLINICAL SIGNIFICANCE

Objective: To explore the expression of vascular endothelial growth factor(VEGF) and basic fibroblast growth factor(bFGF) in non-small cell lung cancer(NSCLC) and theIR clinical significance. Methods: The expression of VEGF and bFGF was examined at the protein levels by immunohistochemical staining in 96 NSCLC patients, and in 36 of which at the mRNA levels by reverse transcription-PCR analysis. Results: VEGF mRNAs were expressed predominately as its secretory forms (VEGF121 and VEGF165) in NSCLC tissues. The positive ratios of VEGF121 and VEGF165 were 69.5%(25 of 36) and 41.7%(15 of 36) respectively. The positive ratio of bFGF was 52.8(19 of 36) in the same tumor specimens. The positive ratios of VEGF and bFGF at protein levels were 55.55%(20 of 36) and 58.33%(21 of 36) respectively. A significant positive correlation was observed between VEGF and bFGF expression in NSCLC tissues(P=0.002). No significant interrelationship between VEGF, bFGF expression and clinical data(age, sex, histological subtype differentiation, P-stage, metastasis and survival) was found. Conclusions: VEGF and bFGF may play an important role in angiogenesis and act in a synergistic manner in NSCLC.

Effect of the implant composite of poly lactide-co-glycolide and bone mesenchymal stem cells modified by basic fibroblast growth factor on injured spinal cord in rats

Objective To investigate the effect of the implant composite of poly lactide-co-glycolide(PLGA)and bone mesenchymal stem cells (BMSCs) modified by basic fibroblast growth factor (bFGF) on injured spinal cord in rats.Methods Two hundred and

Construction and Expression of Recombinant Plasmid pCD-rbFGF in Osteoblasts

Summary: To construct basic fibroblast growth factor (bFGF) eukaryotic expression vector and to evaluate the possibility of bFGF gene therapy in orthopedic disease, the pCD-rbFGF recombinant plasmid was constructed by cloning rat basic fibroblast growth factor (bFGF) cDNA into an eukaryotic expression vector, pcDNA 3. Rat osteoblasts were transfected with pCD-rbFGF plasmid by lopofectin mediated gene transfer, the transient expression was detected by streptavidin-biotin-enzyme complex (SABC) method. It was observed that the expression of rat bFGF gene was detected 72 h after transfected distinctly. Basic fibroblast growth factor gene therapy is a method of potential for a wide array of orthopedic diseases.

Dual growth factor-immobilized microspheres for tissue reinnervation

It has been reported that various progenitor cells or stem cells and continuously released bioactive molecules can enhance the regeneration of muscles and thus help to treat chronic degenerative diseases,such as urinary/fecal incontinence and erectile dysfunction.However,the regeneration ofmuscles alone cannot be a fundamental cure of chronic degenerative diseases,because regenerated muscles with insufficient nerve connections subsequently lead tomuscle atrophy[1].

TAO联合rh-bFGF凝胶对深Ⅱ度烧伤患者症状消失时间及炎症因子的影响

目的探讨复方多粘菌素B软膏(TAO)联合重组牛碱性成纤维细胞生长因子(rh-bFGF)凝胶治疗深Ⅱ度烧伤患者的疗效。方法选取2022年1-11月该院收治的深Ⅱ度烧伤患者60例,采用随机数字表法分观察组和对照组,每组30例。对照组给予TAO治疗,观察组加用rh-bFGF凝胶治疗。对比2组患者临床疗效、症状消失时间、创面愈合时间、换药疼痛、炎症因子、并发症发生率及生活质量。结果观察组患者总有效率明显高于对照组的,并发症发生率明显低于对照组,中、重度疼痛程度明显低于对照组,肿胀消失时间、红斑消失时间、渗液消失时间、水疱消失时间、疼痛消失时间、创面愈合时间均明显短于对照组,差异均有统计学意义(P<0.05)。2组治疗前炎症因子、生活质量比较,差异均无统计学意义(P>0.05);观察组患者治疗后降钙素原、C反应蛋白水平均明显低于对照组,精简烧伤健康量表中的基本生活能力维度、手功能维度、情感维度、人际关系维度、性生活维度、体热维度、热敏感维度、配合治疗维度、工作维度评分均明显高于对照组,差异均有统计学意义(P<0.05)。结论TAO联合rh-bFGF凝胶治疗深Ⅱ度烧伤患者中疗效显著,能加快症状消失及创面愈合,减轻换药疼痛与炎症反应,降低并发症发生率,提高患者生活质量。

bFGF联合超声骨刀在下颌阻生牙拔除中的应用研究

目的:探讨使用重组牛碱性成纤维细胞生长因子(bFGF)联合超声骨刀在拔除下颌阻生牙中的应用效果。方法:根据简单随机分组法将2020年10月至2023年10月来本院进行治疗的下颌阻生牙患者105例分为对照组(n=52)和观察组(n=53);对照组予以bFGF联合常规涡轮钻法拔除,观察组采取bFGF联合超声骨刀法拔除;对比两组手术相关指标,临床治疗效果及术后、肿胀、张口受限恢复情况;对比两组患者龈沟液中炎性因子[肿瘤坏死细胞因子-α(TNF-α)、细胞间粘附因子1(ICAM1)和髓过氧化物酶(MPO)]表达水平及干槽症发生情况。结果:观察组手术时间及术中出血量均小于对照组(P<0.05);手术前后,观察组收缩压、舒张压、血糖水平改善幅度均低于对照组(P<0.05)。观察组治疗优良率为98.11%,高于对照组的82.69%(P<0.05)。两组术后肿胀程度及张口受限发生率比较,观察组均低于对照组(P<0.05)。手术前后,观察组TNF-α、ICAM1和MPO增加幅度均小于对照组(P<0.05)。观察组并发症总发生率低于对照组(P<0.05)。结论:bFGF联合超声骨刀治疗下颌阻生牙疗效确切,可改善龈沟液炎性反应,降低并发症发生风险。

rb-bFGF联合美容缝合技术在儿童颌面部软组织创伤愈合中的应用

目的:探究重组牛碱性成纤维细胞生长因子(Recombinant bovine basic fibroblast growth factor,rb-bFGF)联合美容缝合技术在颌面部软组织创伤愈合的应用。方法:纳入笔者医院整形外科于2023年4月-2023年5月期间收治的72例开放性面部损伤患儿,按照随机数字表法将所有研究对象分为缝合组(n=36)与rb-bFGF组(n=36),缝合组实施美容缝合术,rb-bFGF组在缝合组基础上施加rb-bFGF凝胶治疗,2次/天,持续7 d。比较两组患儿创面愈合情况(愈合时间、表皮生长时间)、并发症发生率,术后7 d,细胞因子水平[干扰素(Interferon-α,INF-α)、人干扰素诱导蛋白10(Interferon induced protein-10,IP-10)及转化生长因子β1(Transforming growth factorβ1,TGF-β1)],术前及术后5个月瘢痕评分[瘢痕评估量表(Patient and observer scar assessment scale,POSAS)、温哥华瘢痕评估量表(Vancouver Scar scale,VSS)]及美学效果满意度。结果:rb-bFGF组患儿创面愈合时间、表皮生长时间均显著短于缝合组(P<0.05);rb-bFGF组并发症发生率(2.78%)与缝合组(11.11%)比较差异无统计学意义(P>0.05);术后7 d,rb-bFGF组INF-α、IP-10水平显著低于缝合组,TGF-β1水平显著高于缝合组(P<0.05);术后5个月,rb-bFGF组POSAS、VSS评分均显著低于缝合组(P<0.05);rb-bFGF组患儿美学效果满意度(94.44%)显著高于缝合组(77.78%)(P<0.05)。结论:rb-bFGF联合美容缝合技术可加快颌面部软组织损伤患儿伤口愈合,改善瘢痕及美观度,并发症较少,安全有效,值得推广。

微针射频联合rb-bFGF凝胶治疗早期面部痤疮瘢痕疗效分析

目的:探讨分析微针射频(Microneedle radiofrequency,MRF)联合重组牛碱性成纤维细胞生长因子(Recombinant bovine basic fibroblast growth factor,rb-bFGF)凝胶治疗早期面部痤疮瘢痕患者的疗效。方法:选取2022年1月-2023年6月马鞍山市妇幼保健院收治的面部痤疮瘢痕患者62例,据简单随机法分为单一组(n=31,MRF治疗)和联合组(n=31,MRF联合rb-bFGF凝胶治疗),2个月1次,共治疗6个月。比较两组临床疗效、水肿时间、红斑消退时间及结痂时间;于治疗前后对比瘢痕基底深度、痤疮瘢痕权重(Echelle d'evaluation clinique des cicatrices d'acne,ECCA)评分、温哥华瘢痕量表(Vancouver scar scale,VSS);并记录不良反应。结果:联合组总有效率较单一组更高(P<0.05)。联合组水肿时间、红斑消退时间及结痂时间均短于单一组(P<0.05)。与治疗前比较,治疗2个月、6个月后两组瘢痕基底深度、ECCA及VSS评分均降低,且联合组上述指标较单一组更低(P<0.05)。联合组不良反应低于单一组(P<0.05)。结论:微针射频联合rb-bFGF凝胶治疗面部痤疮瘢痕患者疗效显著,不仅可改善瘢痕症状,还可促使瘢痕快速恢复,减少不良反应。

纳米银抗菌水凝胶敷料联合rh-bFGF对踝关节开放性骨折术后创面恢复的 影响

目的:探究纳米银抗菌水凝胶敷料联合重组碱性成纤维细胞生长因子(Recombinant human basic fibroblast growth factor,rh-bFGF)对踝关节开放性骨折术后恢复的影响。方法:选取2020年1月-2022年12月于庐江县中医院接受创面修复的97例踝关节开放性骨折患者,按随机数字表法将其分为对照组(n=48例)和观察组(n=49例)。两组均行关节复位固定术,对照组术后予以凡士林敷料进行创面修复,观察组患者予以纳米银抗菌水凝胶敷料联合rh-bFGF进行创面修复。比较两组患者创面修复效果、关节疼痛肿胀情况、血清炎症因子水平[白介素-6(IL-6)、C-反应蛋白(CRP)、肿瘤坏死因子α(TNF-α)]及创面并发症发生情况。结果:观察组治疗总有效率高于对照组(P<0.05),创面血运恢复时间与愈合时间短于对照组(P<0.05);治疗8周后,观察组VAS评分、关节肿胀评分均低于对照组(P<0.05);治疗期间,观察组并发症发生率低于对照组(P<0.05)。结论:纳米银抗菌水凝胶敷料联合rh-bFGF利于踝关节开放性骨折患者术后创面及关节恢复,值得临床推荐。

康复新液联合rb-bFGF对口腔溃疡患儿溃疡面积、症状改善及炎性反应的影响

目的探讨康复新液联合重组牛碱性成纤维细胞生长因子(rb-bFGF)对口腔溃疡患儿溃疡面积、症状改善及炎性反应的影响.方法选择2020年5月—2023年8月兰陵县人民医院收治的80例口腔溃疡患儿为研究对象,按随机数字表法将其分为对照组及观察组,每组40例.对照组采用康复新液治疗,观察组在此基础上采用rb-bFGF治疗,均持续治疗7d.比较两组患儿的症状改善时间、溃疡面积、充血程度、疼痛程度、炎症反应及不良反应发生情况.结果治疗后,观察组的食欲改善、疼痛缓解、溃疡愈合时间分别为(3.05±0.68)d、(3.20±0.92)d、(4.10±1.18)d,均短于对照组,组间差异有统计学意义(P<0.05).治疗后,观察组的溃疡面积、充血程度、疼痛视觉模拟评分分别为(0.87±0.41)分、(0.85±0.24)分、(1.36±0.43)分,均低于对照组,组间差异有统计学意义(P<0.05).治疗后,观察组的肿瘤坏死因子-α、白细胞介素-2、白细胞介素-8水平分别为(185.57±20.42)pg/L、(22.13±4.0)pg/L、(0.38±0.13)μg/L,均低于对照组,组间差异有统计学意义(P<0.05).两组的不良反应发生率比较,差异无统计学意义(P>0.05).结论采用康复新液联合rb-bFGF治疗口腔溃疡患儿,能快速改善症状,减少溃疡面积,缓解充血及疼痛程度,降低炎症反应,且安全性良好.

Effects of recombinant human basic fibroblast growth factor on cell proliferation during mandibular fracture healing in rabbits

Objective:: To investigate the effects of recombinant human basic fibroblast growth factor (rhbFGF) on the cell proliferation during mandibular fracture healing in rabbits. Methods: The complex of rhbFGF and bovine type I collagen was implanted into the mandibular fracture site under periosteum of the animal. The whole mandible was harvested at 7, 14, 28, 56 and 84 days respectively after operation. The expression of proliferating cell nuclear antigen (PCNA) in callus was examined with immunohistochemical staining. Results: PCNA-positive cells in callus in the rhbFGF-treated group on days 7 and 14 were more than that in the control group (P< 0.01 ). Conclusions: It indicates that rhbFGF can stimulate cell proliferation during mandibular fracture healing in rabbits.

bFGF基因转染促进股骨头坏死修复的实验研究

目的 :为临床治疗股骨头及其它骨缺血性坏死探索新方法。方法 :将碱性成纤维细胞生长因子 (bFGF)真核表达质粒pCD rbFGF与胶原混合植入坏死的兔股骨头内 ,术后RT PCR及免疫组化方法检测bFGF表达情况 ,组织切片及组织形态学分析股骨头内血管生长及新骨形成情况。结果 :术后 2周RT PCR及免疫组化证实转染bFGF基因的股骨头内有bFGF表达。术后 2周股骨头内血管生长与对照组相比 ,术后 8周股骨头内新骨形成与对照组相比 ,差异均有非常显著意义 (P <0 .0 1)。结论 :利用bFGF基因转染可刺激股骨头坏死内血管再生和新骨形成 。

以纤维蛋白胶为载体复合BMP和bFGF的注射型骨修复材料诱导异位成骨的实验研究

目的 :了解以纤维蛋白胶 (Fibrinsealant,FS )为载体的注射型骨修复材料异位诱导成骨的作用 ,为其临床的应用提供实验依据。方法 :实验分组为 :实验组b (FS +bFGF+bBMP)、对照组b1(FS +bBMP)、对照组b2 (bBMP)、实验组r (FS +bFGF +rhBMP 2 )、对照组r1(FS +rhBMP)、对照组r2 (rhBMP)、对照组FS及空白对照组。将各组材料注射或植入小鼠肌袋内 ,采用放射学、形态学、碱性磷酸酶 (ALP)检测等方法对其成骨效应进行研究。结果 :在以bBMP为成骨因子的实验区中 ,实验组b具有高效的骨诱导活性 ,其成骨量显著高于对照组b1、对照组b2、对照组FS及空白对照组(P <0 .0 1) ;在以rhBMP 2为成骨因子的实验区中 ,实验组r同样具有高效的骨诱导活性 ,其成骨量也显著高于对照组r1、对照组r2、对照组FS及空白对照组 (P <0 .0 1)。结论 :以FS为载体复合BMP和bFGF的注射型骨修复材料具有高效的骨诱导活性 ,bFGF可明显增强BMP的骨诱导活性。

bFGF、FGF受体I在HEp-2喉癌和MGE803胃癌细胞株中表达的检测

目的 通过对碱性成纤维细胞生长因子 (basicfibroblastgrowthfactor ,bFGF) ,成纤维细胞生长因子受体 1(fibroblastgrowthfactorreceptor 1,FGFR 1)的检测 ,揭示两者在体内外的表达以及与肿瘤形成的关系。 方法 采用免疫组织化学的检测方法 ,检测了体外培养的HEP 2喉癌细胞和MGE80 3胃癌细胞以及由两者在裸鼠皮下形成的实体瘤组织中bFGF和FGFR 1的表达情况。 结果 在体外培养的这两种肿瘤细胞中bFGF的阳性染色存在于整个细胞。FGFR 1的染色主要存在于细胞核。在两种肿瘤细胞形成的实体瘤组织中bFGF和FGFR 1阳性染色细胞主要是围绕于坏死区的肿瘤细胞。 结论 此两种肿瘤细胞在体内外均能表达bFGF和FGFR 1。bFGF与其高亲和力受体FGFR 1结合后进入细胞核 ,并在细胞核内发挥其生物功能 ,参与了肿瘤组织的形成和发展。